{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:26:11Z","timestamp":1769732771250,"version":"3.49.0"},"reference-count":28,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T00:00:00Z","timestamp":1598054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007705","name":"Astellas Pharma Global Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007705","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Treatment patterns and costs were characterized among patients with overactive bladder (OAB) receiving later\u2010line target therapies (combination mirabegron\/antimuscarinic, sacral nerve stimulation [SNS], percutaneous tibial nerve stimulation [PTNS], or onabotulinumtoxinA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In a retrospective cohort study using 2013 to 2017 MarketScan databases, two partially overlapping cohorts of adults with OAB (\u201cIPT cohort\u201d: patients with incident OAB pharmacotherapy use; \u201cITT cohort,\u201d incident target therapy) with continuous enrollment were identified; first use was index. Demographic characteristics, treatment patterns and costs over the 24\u2010month follow\u2010up period were summarized. Crude mean (standard deviation [SD]) OAB\u2010specific (assessed by OAB diagnostic code or pharmaceutical dispensation record) costs were estimated according to target therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The IPT cohort comprised 54\u2009066 individuals (mean [SD] age 58.5 [15.0] years; 76% female), the ITT cohort, 1662 individuals (mean [SD] age 62.8 [14.9] years; 83% female). Seventeen percent of the IPT cohort were treated with subsequent line(s) of therapy after index therapy; among those, 73% received antimuscarinics, 23% mirabegron, and 1.4% a target therapy. For the ITT cohort, 32% were initially treated with SNS, 27% with onabotulinumtoxinA, 26% with combination mirabegron\/antimuscarinic, and 15% with PTNS. Subsequently, one\u2010third of this cohort received additional therapies. Mean (SD) costs were lowest among patients receiving index therapy PTNS ($6959 [$7533]) and highest for SNS ($29\u2009702 [$26\u2009802]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Costs for SNS over 24 months are substantially higher than other treatments. A treatment patterns analysis indicates that oral therapies predominate; first\u2010line combination therapy is common in the ITT cohort and uptake of oral therapy after procedural options is substantial.<\/jats:p><\/jats:sec>","DOI":"10.1002\/nau.24474","type":"journal-article","created":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T12:25:01Z","timestamp":1598099101000},"page":"2206-2222","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United States"],"prefix":"10.1002","volume":"39","author":[{"given":"Stephen R.","family":"Kraus","sequence":"first","affiliation":[{"name":"Department of Urology University of Texas Health Sciences Center, San Antonio, Texas  San Antonio Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9757-6337","authenticated-orcid":false,"given":"Aki","family":"Shiozawa","sequence":"additional","affiliation":[{"name":"Medical Affairs Astellas Pharma Global Development Inc  Northbrook Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelagh M.","family":"Szabo","sequence":"additional","affiliation":[{"name":"Health Economics Broadstreet HEOR  Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Qian","sequence":"additional","affiliation":[{"name":"Health Economics Broadstreet HEOR  Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basia","family":"Rogula","sequence":"additional","affiliation":[{"name":"Health Economics Broadstreet HEOR  Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2098-9058","authenticated-orcid":false,"given":"John","family":"Hairston","sequence":"additional","affiliation":[{"name":"Medical Affairs Astellas Pharma Global Development Inc  Northbrook Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,8,22]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"American Urological Association.Diagnosis and Treatment of Non\u2010Neurogenic Overactive Bladder (OAB) in Adults: an AUA\/SUFU Guideline;2019."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.07.1325"},{"issue":"1","key":"e_1_2_6_4_1","first-page":"47","article-title":"Pelvic floor muscle training versus no treatment for urinary incontinence in women. A Cochrane systematic review","volume":"44","author":"Dumoulin C","year":"2008","journal-title":"Eur J Phys Rehabil Med"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.01.087"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.4111\/icu.2016.57.2.84"},{"issue":"1","key":"e_1_2_6_7_1","first-page":"12","article-title":"A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder","volume":"12","author":"Kennelly MJ","year":"2010","journal-title":"Rev Urol"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.11.010"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22943"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.3098"},{"issue":"2","key":"e_1_2_6_11_1","first-page":"e25","article-title":"Persistence with mirabegron versus tolterodine in patients with overactive bladder","volume":"8","author":"Nitti VW","year":"2016","journal-title":"Am J Pharm Benefits"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12824"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.08.085"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/SPV.0b013e318223c8ad"},{"key":"e_1_2_6_15_1","volume-title":"Silver Spring MD 20993","author":"Gassman MD"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.01.069"},{"key":"e_1_2_6_17_1","first-page":"328","article-title":"Long\u2010term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 Study (SYNERGY II)","volume":"49","author":"Westhofen T","year":"2018","journal-title":"Eur Urol"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.02.030"},{"key":"e_1_2_6_19_1","unstructured":"IBM Watson Health.MarketScan Databases;2018.http:\/\/truvenhealth.com\/markets\/life-sciences\/products\/data-tools\/marketscan-databases. Accessed August 18 2020."},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199801000-00004"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/SPV.0000000000000744"},{"issue":"4","key":"e_1_2_6_22_1","first-page":"e566","article-title":"PD31\u201003 proportion of women with overactive bladder who progress from second\u2010to third\u2010line treatment in a real\u2010world setting","volume":"201","author":"Wolff* E","year":"2019","journal-title":"J Urol"},{"issue":"4","key":"e_1_2_6_23_1","first-page":"e567","article-title":"PD31\u201005 overactive bladder in men: medication abandonment and lack of third\u2010line therapy","volume":"201","author":"Woff E","year":"2019","journal-title":"J Urol"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000462"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.09036.x"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.01.037"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000000286"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000000115"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-017-1385-0"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.24474","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/nau.24474","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.24474","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T01:45:59Z","timestamp":1692841559000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.24474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,22]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1002\/nau.24474"],"URL":"https:\/\/doi.org\/10.1002\/nau.24474","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,22]]},"assertion":[{"value":"2020-02-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}